Kidney Disease in Systemic Amyloidosis: A Review of Amyloid, Amyloid Serum A Protein, Leukocyte Chemotactic Factor 2, and Transthyretin Amyloid.

19 A phase 3 study using birtamimab, which neutralize soluble misfolded FLC, did not reach statistical significance of its primary outcome. 20 Further studies are needed to validate these varied findings.

also in 111,027 other papers